Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Novacyt ( (FR:ALNOV) ).
Novacyt reported audited 2025 results showing group statutory revenue of £20.0m, slightly above market expectations, with underlying revenue up about 4% despite the Taiwan lab divestment and a reduced RUO contribution. Clinical sales climbed to £13.8m on strong NIPT demand, instrumentation revenue jumped more than 25% to £2.5m driven by the LightBench Discover launch, while group EBITDA losses narrowed to £7.8m and post-period cash fell to £11.0m after investment and an earnings-accretive Australian acquisition.
Operationally, the company secured IVDR accreditation for a key Yourgene assay, launched the LightBench Discover platform for long-read sequencing labs and outlined new strategic KPIs, while winning an NHS NIPT contract and acquiring Southern Cross Diagnostics to deepen exposure to the fast-growing Australian and wider APAC diagnostics markets. Management highlighted that the combination of modest top-line growth ahead of expectations, improved profitability metrics and geographic expansion underpins its push toward EBITDA break-even and strengthens its competitive positioning in reproductive health and genomic instrumentation.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics group focused on genomic medicine, developing and commercialising molecular assays and instrumentation for end-to-end workflows from sample to result. Its activities span clinical in vitro diagnostics, DNA sample preparation platforms and research-use-only qPCR and sequencing services across human, animal and environmental health, with operations in Europe, North America and Asia-Pacific, including newly expanded access to Australia.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.